Provitas, LLC v. Quality Ingredients Corporation

Background

Provitas, LLC supplied wholesale vitamins and nutrients, and Quality Ingredients Corporation (QIC) processed liquid ingredients into powders. In 2017, Provitas sent QIC liquid vitamin D2 and D3 for processing. QIC processed the D3 first, performed a dry cleaning of its equipment, and then processed the D2. The court found that the record showed Provitas directed the sequence and the use of a dry clean rather than a full “Clean in Place” wash.

Provitas later shipped the processed D2 to DSM Nutritional Products. DSM used it in a soy-milk premix intended for vegetarian and vegan consumers. Testing found vitamin D3 in the premix; because D3 is derived from animal products, DSM said the premix could not be sold to those consumers and destroyed the batch. DSM demanded more than $1.8 million from Provitas, and the parties eventually reached a confidential settlement.

Provitas brought five claims: indemnity under Texas law, a Texas Deceptive Trade Practices Act claim, a claim alleging violation of the federal Food and Drug Administration’s Current Good Manufacturing Practices, breach of express warranty, and breach of implied warranties of merchantability and fitness for a particular purpose. QIC moved for summary judgment, arguing that Minnesota law applied, that the federal regulations created no private right to sue, and that the warranty and indemnity claims lacked adequate support.

Choice of Law and Indemnity Claims

The court applied Minnesota conflict-of-law rules because the case was in federal court based on diversity jurisdiction. It held that the Mutual Confidentiality Agreement’s provision governing the agreement and the parties’ relationship under Minnesota law covered Provitas’ Texas statutory claims. The court also concluded that enforcing the provision was not arbitrary or unfair because QIC was incorporated and operated in Minnesota and the vitamin processing occurred there. The court therefore held that Minnesota law precluded Provitas’ Texas claims.

Provitas argued that it could rely on QIC’s Continuing Product Guaranty to support indemnity. The court construed that argument as one for contractual indemnification, but held that the complaint did not mention the guaranty and Provitas had not moved to amend its complaint. The court further noted that Provitas had not submitted the confidential settlement agreement or shown that the settlement was reasonable, and had not established other requirements of the indemnity provision. The court granted QIC summary judgment on Provitas’ indemnity claims, identified as Counts I and II in the order.

Federal Manufacturing-Practices Claim

The court granted summary judgment to QIC on Count III. It held that the federal Food, Drug, and Cosmetic Act authorizes enforcement proceedings in the name of the United States, not through a private lawsuit. Because Provitas sought to directly enforce the Current Good Manufacturing Practices and did not address QIC’s argument or contrary authority, the claim could not proceed.

Express-Warranty Claim

The court granted summary judgment to QIC on Count IV. Provitas identified the Continuing Product Guaranty and the vitamin D2 labels as possible sources of express warranties. The court questioned reliance on the guaranty because Provitas had not pleaded it as the basis for the claim or identified it during discovery. Even assuming the guaranty created a warranty, the court found no genuine dispute that QIC breached it. The evidence showed that Provitas directed the dry-cleaning process, and Provitas did not provide sufficient evidence that the processed product was adulterated under the federal law referenced in the guaranty.

The label theory also failed because the record showed that Provitas, not QIC, created the labels, and the labels stated that Provitas guaranteed the product. The court found Provitas’ allegations insufficient to create a genuine factual dispute.

Implied-Warranty Claims

The court granted summary judgment to QIC on Count V. The fitness-for-a-particular-purpose claim failed because neither Provitas nor QIC knew that the product was intended for a vegan or vegetarian food product. The court held that knowledge of the general use of processed vitamins in food manufacturing was not enough to establish knowledge of this particular purpose.

The merchantability claim also failed. Provitas did not provide evidence that the presence of vitamin D3 made the D2 mixture unsafe, spoiled, sickening, or otherwise unfit for its ordinary purpose. It also did not identify a contract term, specification, regulation, or expert opinion showing what amount of D3 would make the product unmerchantable. The court concluded that speculation did not create a genuine dispute of material fact.

Disposition

Judge Susan Richard Nelson granted QIC’s Motion for Summary Judgment. The order granted summary judgment to QIC on all of Provitas’ claims and directed that judgment be entered accordingly.